Earkart Ltd has announced a board meeting scheduled for March 30, 2026, to deliberate on crucial matters related to its Initial Public Offering (IPO) proceeds utilization. The company has formally notified BSE Limited about this upcoming meeting in compliance with regulatory requirements.

Board Meeting Agenda

The primary focus of the board meeting will be to consider and approve variation in the objects and terms of utilization of IPO proceeds. Additionally, the board will discuss the extension of time limit for utilization of these proceeds.

Regulatory Compliance

The announcement was made pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates prior intimation of board meetings to stock exchanges when specific matters are to be considered.

The formal communication was sent to the Corporate Relationship Department of BSE Limited on March 20, 2026. The company has assured that relevant information will be made available on its official website at https://www.earkart.in .

Company Information

The communication was signed by Preeti Srivastava, Company Secretary & Compliance Officer (Membership No: A31615), and was digitally signed on March 20, 2026, from the company's Noida office. This board meeting represents a significant corporate governance activity as the company seeks to modify its IPO proceeds utilization framework.

Earkart Limited announced that its Board of Directors has approved two major strategic acquisitions during a meeting held on 11 March 2026. The decisions mark significant expansion moves for the company as it seeks to strengthen its manufacturing capabilities and enter the pharmaceutical sector.

Board Meeting Outcomes

The board meeting, conducted under Regulations 30 and 42 of SEBI Listing Regulations, addressed critical business expansion initiatives. The session ran from 11:30 AM to 1:20 P.M., with directors deliberating on strategic acquisition opportunities.

Strategic Acquisitions Approved

The board approved two key acquisitions that will expand Earkart Limited's operational footprint. The first involves acquiring land specifically designated for establishing a new manufacturing facility, which will enhance the company's production capabilities. The second approval covers the acquisition of a pharmaceutical business, representing the company's strategic entry into the healthcare sector.

Compliance Acknowledgment

Earkart Limited acknowledged that the board meeting was convened on shorter notice due to the urgent nature of matters requiring immediate attention. Company Secretary Preeti Srivastava clarified that the necessary intimation to BSE, as required under Regulation 29 of SEBI LODR Regulations, was not provided within the stipulated timeframe.

The company emphasized that the delay in intimation was solely due to the urgency of matters and not due to compliance oversight. Management assured stakeholders that necessary steps are being implemented to ensure such delays do not occur in future proceedings.

Corporate Governance

The company maintains its commitment to adhering to SEBI compliance requirements and has requested BSE to take the clarification on record. All meeting outcomes and related documentation will be made available on the company's website at https://earkart.com for stakeholder reference.

Company Secretary Preeti Srivastava, with membership number A31615, signed the regulatory filings digitally on 11 March 2026, ensuring proper documentation of the board decisions and compliance clarifications.